Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Daniel Woronow"'
Autor:
Anton Pottegård, Rebecca E Ghosh, Robert W Platt, Efe Eworuke, HaNa Lee, Marie C Bradley, Ashish Rai, Peter Bjødstrup Jensen, Mayura Shinde, Laura Hou, Michael J Paterson, Judith C Maro, Daniel Scarnecchia, Dinci Pennap, Daniel Woronow, Stephen Welburn
Publikováno v:
BMJ Open, Vol 13, Iss 4 (2023)
Objectives To examine valsartan, losartan and irbesartan usage and switching patterns in the USA, UK, Canada and Denmark before and after July 2018, when the first Angiotensin-Receptor-Blocker (ARB) (valsartan) was recalled.Design Retrospective cohor
Externí odkaz:
https://doaj.org/article/1a9e38df6e294a2abc497e762ff2c878
Autor:
Daniel Woronow, Christine Chamberlain, Ali Niak, Mark Avigan, Monika Houstoun, Cindy Kortepeter
Publikováno v:
JAMA internal medicine. 182(10)
This case series identifies cases reported in the US Food and Drug Administration Adverse Event Reporting System of acute cholecystitis associated with use of glucagon-like peptide-1 receptor agonists that did not have gallbladder disease warnings in
Autor:
Efe Eworuke, Mayura Shinde, Laura Hou, Michael J Paterson, Peter Bjødstrup Jensen, Judith C Maro, Ashish Rai, Daniel Scarnecchia, Dinci Pennap, Daniel Woronow, Rebecca E Ghosh, Stephen Welburn, Anton Pottegard, Robert W Platt, Hana Lee, Marie C Bradley
Publikováno v:
BMJ Open. 13:e070985
ObjectivesTo examine valsartan, losartan and irbesartan usage and switching patterns in the USA, UK, Canada and Denmark before and after July 2018, when the first Angiotensin-Receptor-Blocker (ARB) (valsartan) was recalled.DesignRetrospective cohort
Autor:
Michelle C, Nadeau Nguyen, Daniel, Woronow, Bailee, Binks, Afrouz, Nayernama, S Christopher, Jones
Publikováno v:
JACC: CardioOncology
Autor:
Michelle Nadeau Nguyen, Laleh Amiri-Kordestani, Daniel Woronow, Afrouz Nayernama, Michael Brave, S. Christopher Jones, Sundeep Agrawal, Connie Cheng
Publikováno v:
Vascular medicine (London, England). 26(5)
The US Food and Drug Administration (FDA) has approved multiple systemic vascular endothelial growth factor (VEGF) inhibitors since 2004 to treat various malignancies. Inhibition of the VEGF signaling pathway can result in impairment of vascular wall
Publikováno v:
American Journal of Hematology. 93:E333-E336
Publikováno v:
Journal of Vascular Surgery: Venous and Lymphatic Disorders. 7:311-313
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522110157
Autor:
Lynda McCulley, Page E. Crew, Mohamed Mohamoud, Daniel Woronow, Gerald J. Dal Pan, Saharat Patanavanich, Monica A. Muñoz, S. Christopher Jones, Cindy Kortepeter
Publikováno v:
Ann Pharmacother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c642b6a1010fff2d62cb3a056c32097d
https://europepmc.org/articles/PMC8919214/
https://europepmc.org/articles/PMC8919214/
Publikováno v:
JACC: CardioOncology. 3:165